United Therapeutics CorporationUTHRNASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-4.85%
↓ 102% below average
Average (39q)
263.22%
Historical baseline
Range
High:8900.00%
Low:-100.53%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -4.85% |
| Q2 2025 | -10.07% |
| Q1 2025 | 11.36% |
| Q4 2024 | 29.28% |
| Q3 2024 | -25.86% |
| Q2 2024 | 34.10% |
| Q1 2024 | -31.24% |
| Q4 2023 | 78.75% |
| Q3 2023 | -4.83% |
| Q2 2023 | 7.36% |
| Q1 2023 | -11.71% |
| Q4 2022 | 42.06% |
| Q3 2022 | -29.61% |
| Q2 2022 | 36.09% |
| Q1 2022 | -16.77% |
| Q4 2021 | 4.67% |
| Q3 2021 | 6.59% |
| Q2 2021 | -75.54% |
| Q1 2021 | 140.84% |
| Q4 2020 | 83.55% |
| Q3 2020 | -23.41% |
| Q2 2020 | 22.54% |
| Q1 2020 | -35.56% |
| Q4 2019 | 32.56% |
| Q3 2019 | -0.23% |
| Q2 2019 | -90.43% |
| Q1 2019 | 546.54% |
| Q4 2018 | 37.29% |
| Q3 2018 | 22.84% |
| Q2 2018 | 130.53% |
| Q1 2018 | -68.57% |
| Q4 2017 | 106.55% |
| Q3 2017 | -8.03% |
| Q2 2017 | 65.19% |
| Q1 2017 | -45.89% |
| Q4 2016 | 45.75% |
| Q3 2016 | 30.40% |
| Q2 2016 | 8900.00% |
| Q1 2016 | -100.53% |
| Q4 2015 | 697.19% |